DTILNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends May 21
PRECISION BIOSCIENCES INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$6.19+0.42 (+7.28%)
Close on Oct 19, 2026
- Market cap
- $160.05M
- P/E (TTM)
- –
- Dividend yield
- –
PRECISION BIOSCIENCES INC revenue by segment
By business segment
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q4 21 | TTM Q3 21 | TTM Q2 21 | TTM Q1 21 | TTM Q4 20 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Segment | $45.06M | $45.07M | $34.26M | $698.00K | $1.26M | $51.14M | $68.70M | – | – | – | – | – | 100.0% | +3473.0% |
| Therapeutics | – | – | – | – | – | – | – | $111.72M | $114.68M | $98.94M | $32.07M | $21.86M | – | – |
| Food | – | – | – | – | – | – | – | $3.81M | $3.35M | $2.43M | $1.57M | $2.42M | – | – |
| Operating income | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q4 21 | TTM Q3 21 | TTM Q2 21 | TTM Q1 21 | TTM Q4 20 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Segment | -$36.40M | -$39.11M | -$52.15M | -$89.50M | -$90.11M | -$44.09M | -$26.16M | – | – | – | – | – | -59.6% |
| Therapeutics | – | – | – | – | – | – | – | $31.98M | $36.49M | $21.25M | -$43.38M | -$49.98M | – |
| Food | – | – | – | – | – | – | – | -$3.83M | -$4.35M | -$5.01M | -$5.49M | -$5.17M | – |
By product or service
By region
From the segment and revenue-disaggregation notes of Precision Biosciences's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.